Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study.
The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks.
Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time the company says is typically associated with interstitial glucose measurements. Glucotrack’s long-term implantable device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution.
Glucotrack plans for the short-term, prospective, single-arm in-hospital study to place the CBGM sensor intravascularly for four days. Participants will take part in several fixed meal and glucose challenges during the study period.
Dr. Alexandre Abizaid of the Instituto do Coração in São Paulo, Brazil, serves as principal investigator.
“Following the success of our preclinical program, we are pleased to reach this key milestone in the development of our novel CBGM,” said Paul V. Goode, president & CEO of Glucotrack. “We believe this groundbreaking early feasibility study will demonstrate the potential for our real-time continuous blood glucose monitor to offer a truly differentiated and less burdensome approach to glucose monitoring for people with diabetes.”
